toxylact
The first professional lActological database in the word
Prednisolone enemas and foams in ATC class A07EA01 are locally acting intestinal corticosteroids with low systemic bioavailability, generally compatible with breastfeeding when used short term and with monitoring of the infant for corticosteroid-related effects.atcddd.fhi+1
ATC class and general pharmacology
ATC code A07EA belongs to the therapeutic subgroup “antidiarrheals, intestinal anti-inflammatory/anti-infective agents” within the alimentary tract and metabolism group (A), and A07EA specifically denotes “corticosteroids acting locally”. Within this subgroup, A07EA01 corresponds to prednisolone formulations intended as enemas and rectal foams for treatment of inflammatory bowel disease such as ulcerative colitis, where the therapeutic intent is predominantly local mucosal anti-inflammatory action in the distal colon and rectum.wikipedia+2
Prednisolone is a synthetic glucocorticoid that exerts its primary pharmacodynamic effect via high-affinity binding to cytosolic glucocorticoid receptors, modulating gene transcription and downregulating pro‑inflammatory cytokines, adhesion molecules, and inflammatory enzymes. Systemically, glucocorticoids reduce capillary permeability, inhibit leukocyte migration, and suppress cell-mediated immunity; when administered rectally in A07EA01 preparations, the formulation and route are chosen to maximize luminal and mucosal exposure while limiting systemic absorption compared with equivalent oral doses.atcddd.fhi+1
Rectal prednisolone enemas and foams provide high local concentrations in the distal colon, leading to more rapid symptom relief in distal ulcerative colitis compared with non‑steroidal topical agents, especially when disease activity is moderate. Oral prednisolone products exist under other ATC codes, but the A07EA01 classification emphasizes products whose pharmacokinetic design and approved indications regard them as locally acting intestinal corticosteroids, even though some systemic exposure still occurs.atcddd.fhi+3
Toxicological profile
The toxicological profile of prednisolone is typical of glucocorticoids, with dose- and duration-dependent risks that are well characterized from systemic formulations; however, rectal preparations generally yield lower systemic exposure and therefore a lower incidence and magnitude of systemic adverse effects at equivalent anti‑inflammatory efficacy in distal colitis. Acute toxicity of prednisolone in animal models is relatively low, with high oral LD50 values, but chronic and subchronic exposure is associated with characteristic glucocorticoid toxicities, including adrenal suppression, metabolic disturbances, and growth inhibition, underscoring the importance of limiting prolonged systemic exposure even when rectal routes are used.caymanchem+3
Systemic glucocorticoid‑related adverse effects include hypothalamic‑pituitary‑adrenal (HPA) axis suppression, Cushingoid features, hypertension, glucose intolerance, dyslipidemia, osteopenia or osteoporosis, myopathy, cataracts, and increased susceptibility to infection; these effects are primarily linked to cumulative systemic exposure and duration, so the risk from short‑course rectal prednisolone enemas is lower but not negligible, especially at high doses or in patients with impaired mucosa that enhances absorption. Local adverse effects at the rectal administration site can include irritation, discomfort, and, rarely, local infection or fissuring; systemic toxicological concerns also extend to potential effects on fertility and reproduction at high exposures seen in animal toxicology, although these are unlikely at therapeutic doses of locally acting enemas.caymanchem+1
From a toxicological‑environmental perspective, glucocorticoids like prednisolone are classified as slightly hazardous for water in safety data sheets, and improper disposal of concentrated pharmaceutical products should be avoided to minimize aquatic exposure. Specific target organ toxicity with repeated systemic glucocorticoid exposure involves the adrenal glands and bone, with sustained suppression of endogenous cortisol and increased bone resorption, but rectal formulations at standard doses do not typically achieve systemic levels associated with severe organ toxicity in adults when used for short periods.caymanchem+2
Lactation pharmacology and infant exposure
Drug transfer into human milk is governed by physicochemical and pharmacokinetic factors such as molecular weight, lipophilicity, protein binding, pKa, volume of distribution, and half‑life; high protein binding, higher molecular weight, low lipid solubility, and short half‑life generally limit milk transfer and infant exposure. Drugs enter breast milk predominantly by passive diffusion from maternal plasma, so maternal systemic exposure is the primary driver of milk concentrations; locally acting formulations with poor systemic absorption, such as rectal prednisolone enemas in A07EA01, therefore tend to produce lower milk levels than equivalent systemic oral or intravenous dosing.accp+2
General principles of lactation pharmacology emphasize that medications with poor oral bioavailability and those acting locally in the gastrointestinal tract are less likely to cause clinically relevant effects in the breastfed infant, because the fraction that reaches milk may be small and the fraction absorbed from the infant gut may be even smaller. Prednisolone, when administered systemically, is known to appear in breast milk at low concentrations, and relative infant doses reported for typical maternal oral regimens are generally below the 10% threshold often used as a pragmatic safety cut‑off, though higher doses or prolonged therapy increase infant exposure.ncbi.nlm.nih+2
For rectal prednisolone in A07EA01, the local route and reduced systemic bioavailability compared with oral formulations mean that maternal plasma concentrations and subsequent milk transfer are expected to be lower for a given anti‑inflammatory effect, especially when treatment courses are short and confined to distal colitis. In the breastfed infant, any prednisolone that reaches milk is further subject to oral first‑pass metabolism and incomplete absorption, which further reduces systemic exposure in the infant, particularly in older infants with more mature drug‑metabolizing capacity.atcddd.fhi+3
Lactological safety assessment and clinical recommendations
Risk assessment frameworks for medications in lactation emphasize weighing maternal benefit against potential infant risk, preferentially selecting drugs and formulations with low systemic availability, short half‑life, and low oral bioavailability in the infant. Topical and locally acting medications are generally considered safer than systemic ones in lactation, provided they are not applied directly on the nipple or in a way that the infant ingests high amounts; rectal prednisolone enemas in A07EA01 fit this pattern, as they are designed for local intestinal action with limited systemic absorption.atcddd.fhi+2
Given the pharmacology and expected low systemic exposure, prednisolone enemas and foams in A07EA01 are generally compatible with breastfeeding when used in standard doses and limited duration for distal ulcerative colitis, especially when no suitable non‑steroidal alternative can achieve comparable disease control. Clinical recommendations typically favor continuing breastfeeding during maternal corticosteroid therapy if the maternal regimen uses the lowest effective dose, avoids prolonged high‑dose systemic exposure, and includes clinical monitoring of the infant for potential glucocorticoid effects such as poor weight gain, unusual lethargy, or signs of adrenal suppression.ncbi.nlm.nih+2
When repeated or prolonged courses of rectal prednisolone are required, or when combined with systemic corticosteroids, clinicians should reassess infant exposure by considering total maternal dose, treatment duration, and any infant comorbidities that might increase susceptibility, such as prematurity or low birth weight. In such higher‑risk scenarios, strategies such as timing maternal dosing immediately after breastfeeding, monitoring infant growth and behavior, and, if needed, measuring infant cortisol or other markers can help mitigate risk while preserving breastfeeding whenever possible.ncbi.nlm.nih+3
For mothers with stable disease on minimal effective rectal corticosteroid doses, routine laboratory monitoring of the infant is not usually required, and reassurance coupled with clear counseling about potential signs to watch for is often sufficient. Interrupting breastfeeding (“pumping and dumping”) solely because of short‑term treatment with locally acting rectal prednisolone is generally discouraged, as even brief interruptions can jeopardize breastfeeding continuation and may not meaningfully reduce infant exposure compared with optimized timing and dosing strategies.ncbi.nlm.nih+2



